{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T12:02:12Z","timestamp":1742385732123,"version":"3.37.3"},"reference-count":8,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,3]]},"DOI":"10.1093\/brain\/awad165","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T17:26:48Z","timestamp":1684171608000},"page":"e80-e82","source":"Crossref","is-referenced-by-count":1,"title":["Reply: A new diagnostic entity must enable earlier treatment in gene carriers"],"prefix":"10.1093","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0094-5429","authenticated-orcid":false,"given":"Michael","family":"Benatar","sequence":"first","affiliation":[{"name":"Department of Neurology, University of Miami Miller School of Medicine , Miami, FL 33136 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4924-7712","authenticated-orcid":false,"given":"Ammar","family":"Al-Chalabi","sequence":"additional","affiliation":[{"name":"Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King\u2019s College London , London, SE5 9RX , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Crawley","sequence":"additional","affiliation":[{"name":"Buffalo, NY 14220, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne","family":"Wuu","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Miami Miller School of Medicine , Miami, FL 33136 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,5,15]]},"reference":[{"key":"2024041009322775200_awad165-B1","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1093\/brain\/awad164","article-title":"A new diagnostic entity must enable earlier treatment in gene carriers","volume":"146","author":"Swidler","year":"2023","journal-title":"Brain"},{"key":"2024041009322775200_awad165-B2","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1093\/brain\/awac185","article-title":"Mild motor impairment as prodromal state in amyotrophic lateral sclerosis: A new diagnostic entity","volume":"145","author":"Benatar","year":"2022","journal-title":"Brain"},{"key":"2024041009322775200_awad165-B3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/brain\/awab404","article-title":"Preventing amyotrophic lateral sclerosis: Insights from pre-symptomatic neurodegenerative diseases","volume":"145","author":"Benatar","year":"2022","journal-title":"Brain"},{"key":"2024041009322775200_awad165-B4","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1136\/bmj.317.7171.1521a","article-title":"People should participate in, not be subjects of, research","volume":"317","author":"Boynton","year":"1998","journal-title":"BMJ"},{"key":"2024041009322775200_awad165-B5","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1212\/WNL.0b013e31826e9b1d","article-title":"Presymptomatic studies in ALS: Rationale, challenges, and approach","volume":"79","author":"Benatar","year":"2012","journal-title":"Neurology"},{"key":"2024041009322775200_awad165-B6","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/ana.25276","article-title":"Neurofilament light: A candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion","volume":"84","author":"Benatar","year":"2018","journal-title":"Ann Neurol."},{"key":"2024041009322775200_awad165-B7","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1007\/s13311-022-01237-4","article-title":"Design of a randomized, placebo-controlled, phase 3 trial of tofersen initiated in clinically presymptomatic SOD1 variant carriers: The ATLAS study","volume":"19","author":"Benatar","year":"2022","journal-title":"Neurotherapeutics"},{"key":"2024041009322775200_awad165-B8","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1136\/jnnp-2022-330473","article-title":"A roadmap to ALS prevention: Strategies and priorities","volume":"94","author":"Benatar","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Brain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/brain\/advance-article-pdf\/doi\/10.1093\/brain\/awad165\/50493518\/awad165.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/146\/10\/e80\/57196194\/awad165.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/146\/10\/e80\/57196194\/awad165.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T09:38:49Z","timestamp":1712741929000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/brain\/article\/146\/10\/e80\/7162996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,15]]},"references-count":8,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,5,15]]},"published-print":{"date-parts":[[2023,10,3]]}},"URL":"https:\/\/doi.org\/10.1093\/brain\/awad165","relation":{},"ISSN":["0006-8950","1460-2156"],"issn-type":[{"type":"print","value":"0006-8950"},{"type":"electronic","value":"1460-2156"}],"subject":[],"published-other":{"date-parts":[[2023,10]]},"published":{"date-parts":[[2023,5,15]]}}}